Cargando…
Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis
Objective To compare the use of mirabegron with anticholinergics drugs for the treatment of overactive bladder (OB). Data Source Systematic searches were conducted in EMBASE, PUBMED, Cochrane, and LILACS databases from inception to September 2021. We included RCTs, women with clinically proven OB...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Thieme Revinter Publicações Ltda.
2023
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371066/ https://www.ncbi.nlm.nih.gov/pubmed/37494577 http://dx.doi.org/10.1055/s-0043-1770093 |
_version_ | 1785078074581188608 |
---|---|
author | Sartori, Luisa Gracio Ferreira Nunes, Bruno Monteiro Farah, Daniela Oliveira, Leticia Maria de Novoa, Claudia Cristina Takano Sartori, Marair Gracio Ferreira Fonseca, Marcelo Cunio Machado |
author_facet | Sartori, Luisa Gracio Ferreira Nunes, Bruno Monteiro Farah, Daniela Oliveira, Leticia Maria de Novoa, Claudia Cristina Takano Sartori, Marair Gracio Ferreira Fonseca, Marcelo Cunio Machado |
author_sort | Sartori, Luisa Gracio Ferreira |
collection | PubMed |
description | Objective To compare the use of mirabegron with anticholinergics drugs for the treatment of overactive bladder (OB). Data Source Systematic searches were conducted in EMBASE, PUBMED, Cochrane, and LILACS databases from inception to September 2021. We included RCTs, women with clinically proven OB symptoms, studies that compared mirabegron to antimuscarinic drugs, and that evaluated the efficacy, safety or adherence. Data Collection RevMan 5.4 was used to combine results across studies. We derived risk ratios (RRs) and mean differences with 95% CIs using a random-effects meta-analytic model. Cochrane Collaboration Tool and GRADE was applied for risk of bias and quality of the evidence. Data Synthesis We included 14 studies with a total of 10,774 patients. Fewer total adverse events was reported in mirabegron group than in antimuscarinics group [RR 0.93 (0.89–0.98)]. The risk of gastrointestinal tract disorders and dry mouth were lower with mirabegron [RR 0,58 (0.48–0.68); 9375 patients; RR 0.44 (0.35–0.56), 9375 patients, respectively]. No difference was reported between mirabegron and antimuscarinics drugs for efficacy. The adherence to treatment was 87.7% in both groups [RR 0.99 (0.98–1.00)]. Conclusion Mirabegron and antimuscarinics have comparable efficacy and adherence rates; however, mirabegron showed fewer total and isolated adverse events. |
format | Online Article Text |
id | pubmed-10371066 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Thieme Revinter Publicações Ltda. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103710662023-07-27 Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis Sartori, Luisa Gracio Ferreira Nunes, Bruno Monteiro Farah, Daniela Oliveira, Leticia Maria de Novoa, Claudia Cristina Takano Sartori, Marair Gracio Ferreira Fonseca, Marcelo Cunio Machado Rev Bras Ginecol Obstet Objective To compare the use of mirabegron with anticholinergics drugs for the treatment of overactive bladder (OB). Data Source Systematic searches were conducted in EMBASE, PUBMED, Cochrane, and LILACS databases from inception to September 2021. We included RCTs, women with clinically proven OB symptoms, studies that compared mirabegron to antimuscarinic drugs, and that evaluated the efficacy, safety or adherence. Data Collection RevMan 5.4 was used to combine results across studies. We derived risk ratios (RRs) and mean differences with 95% CIs using a random-effects meta-analytic model. Cochrane Collaboration Tool and GRADE was applied for risk of bias and quality of the evidence. Data Synthesis We included 14 studies with a total of 10,774 patients. Fewer total adverse events was reported in mirabegron group than in antimuscarinics group [RR 0.93 (0.89–0.98)]. The risk of gastrointestinal tract disorders and dry mouth were lower with mirabegron [RR 0,58 (0.48–0.68); 9375 patients; RR 0.44 (0.35–0.56), 9375 patients, respectively]. No difference was reported between mirabegron and antimuscarinics drugs for efficacy. The adherence to treatment was 87.7% in both groups [RR 0.99 (0.98–1.00)]. Conclusion Mirabegron and antimuscarinics have comparable efficacy and adherence rates; however, mirabegron showed fewer total and isolated adverse events. Thieme Revinter Publicações Ltda. 2023-07-21 /pmc/articles/PMC10371066/ /pubmed/37494577 http://dx.doi.org/10.1055/s-0043-1770093 Text en Federação Brasileira de Ginecologia e Obstetrícia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. ( https://creativecommons.org/licenses/by/4.0/ ) https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Sartori, Luisa Gracio Ferreira Nunes, Bruno Monteiro Farah, Daniela Oliveira, Leticia Maria de Novoa, Claudia Cristina Takano Sartori, Marair Gracio Ferreira Fonseca, Marcelo Cunio Machado Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis |
title | Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis |
title_full | Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis |
title_fullStr | Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis |
title_full_unstemmed | Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis |
title_short | Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis |
title_sort | mirabegron and anticholinergics in the treatment of overactive bladder syndrome: a meta-analysis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371066/ https://www.ncbi.nlm.nih.gov/pubmed/37494577 http://dx.doi.org/10.1055/s-0043-1770093 |
work_keys_str_mv | AT sartoriluisagracioferreira mirabegronandanticholinergicsinthetreatmentofoveractivebladdersyndromeametaanalysis AT nunesbrunomonteiro mirabegronandanticholinergicsinthetreatmentofoveractivebladdersyndromeametaanalysis AT farahdaniela mirabegronandanticholinergicsinthetreatmentofoveractivebladdersyndromeametaanalysis AT oliveiraleticiamariade mirabegronandanticholinergicsinthetreatmentofoveractivebladdersyndromeametaanalysis AT novoaclaudiacristinatakano mirabegronandanticholinergicsinthetreatmentofoveractivebladdersyndromeametaanalysis AT sartorimarairgracioferreira mirabegronandanticholinergicsinthetreatmentofoveractivebladdersyndromeametaanalysis AT fonsecamarcelocuniomachado mirabegronandanticholinergicsinthetreatmentofoveractivebladdersyndromeametaanalysis |